Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that mogamulizumab-associated rashes and alopecia are common in patients treated for mycosis fungoides and Sézary syndrome and may be linked with a good treatment response.

In this case report, mogamulizumab treatment for Sézary syndrome was associated with rashes and alopecia in a patient, highlighting the potential for immune-mediated side effects and suggesting that such adverse effects might indicate a favorable prognosis, though further studies are needed.

This study highlights that although mogamulizumab is highly effective for treating mycosis fungoides and Sézary syndrome, it frequently causes a variety of rashes as side effects.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This study found that oral spironolactone improved or maintained hair condition in females with scarring alopecia and female pattern hair loss, with 83% of patients tolerating the treatment well, despite some side effects like hyperkalemia and leg cramps.